FI20055562A - Alfa-interferonin stabiilit vesiliuosformulaatit - Google Patents

Alfa-interferonin stabiilit vesiliuosformulaatit Download PDF

Info

Publication number
FI20055562A
FI20055562A FI20055562A FI20055562A FI20055562A FI 20055562 A FI20055562 A FI 20055562A FI 20055562 A FI20055562 A FI 20055562A FI 20055562 A FI20055562 A FI 20055562A FI 20055562 A FI20055562 A FI 20055562A
Authority
FI
Finland
Prior art keywords
alfa
aqueous solution
interferon
stable aqueous
alpha interferon
Prior art date
Application number
FI20055562A
Other languages
English (en)
Swedish (sv)
Other versions
FI117377B (fi
Inventor
Pui-Ho Yuen
Douglas Kline
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of FI20055562A publication Critical patent/FI20055562A/fi
Application granted granted Critical
Publication of FI117377B publication Critical patent/FI117377B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
FI20055562A 1994-10-11 2005-10-19 Kelatointiaineen käyttö alfatyyppistä interferonia sisältävässä, stabiilissa vesiformulaatiossa FI117377B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32981394 1994-10-11
US08/329,813 US5766582A (en) 1994-10-11 1994-10-11 Stable, aqueous alfa interferon solution formulations
US9512362 1995-10-10
PCT/US1995/012362 WO1996011018A1 (en) 1994-10-11 1995-10-10 Stable, aqueous alfa interferon solution formulations

Publications (2)

Publication Number Publication Date
FI20055562A true FI20055562A (fi) 2005-10-19
FI117377B FI117377B (fi) 2006-09-29

Family

ID=23287133

Family Applications (2)

Application Number Title Priority Date Filing Date
FI971486A FI116558B (fi) 1994-10-11 1997-04-10 Alfa-interferonin stabiilit vesiliuosformulaatiot
FI20055562A FI117377B (fi) 1994-10-11 2005-10-19 Kelatointiaineen käyttö alfatyyppistä interferonia sisältävässä, stabiilissa vesiformulaatiossa

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FI971486A FI116558B (fi) 1994-10-11 1997-04-10 Alfa-interferonin stabiilit vesiliuosformulaatiot

Country Status (25)

Country Link
US (2) US5766582A (fi)
EP (2) EP0970703B1 (fi)
JP (2) JP3978228B2 (fi)
KR (1) KR100401401B1 (fi)
CN (1) CN1102408C (fi)
AT (2) ATE245033T1 (fi)
AU (1) AU708337B2 (fi)
BR (1) BR9509313A (fi)
CA (1) CA2201749C (fi)
CZ (1) CZ296961B6 (fi)
DE (2) DE69518084T2 (fi)
DK (1) DK0777495T3 (fi)
ES (2) ES2198830T3 (fi)
FI (2) FI116558B (fi)
GR (1) GR3034619T3 (fi)
HK (1) HK1008813A1 (fi)
HU (1) HU225494B1 (fi)
NO (1) NO320604B1 (fi)
NZ (1) NZ294464A (fi)
PL (1) PL183797B1 (fi)
PT (1) PT777495E (fi)
RU (1) RU2157236C2 (fi)
SK (1) SK282949B6 (fi)
UA (1) UA42028C2 (fi)
WO (1) WO1996011018A1 (fi)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
BR9909087A (pt) * 1998-03-26 2000-12-05 Schering Corp Formulações para proteção de conjugados peg-alfa interferon
KR100694345B1 (ko) 1998-05-15 2007-03-12 쉐링 코포레이션 리바비린 및 인터페론 알파를 포함하는, 만성 ｃ형 간염에 걸린 항-바이러스 치료에 대한 나이브 환자의 치료용 약제학적 조성물
US6281337B1 (en) 1998-11-12 2001-08-28 Schering Corporation Methods for conversion of protein isoforms
JP4468585B2 (ja) 1998-11-12 2010-05-26 シェーリング コーポレイション インターフェロンアイソフォームおよびその産物の変換の方法
US7402559B2 (en) * 1999-03-24 2008-07-22 Msh Pharma, Incorporated Composition and method of treatment for urogenital conditions
JP3712914B2 (ja) * 1999-04-08 2005-11-02 シェーリング コーポレイション 腎細胞ガン処置
CN1390132A (zh) 1999-04-08 2003-01-08 先灵公司 聚乙二醇化干扰素α在黑素瘤治疗中的应用
US6923966B2 (en) * 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
ES2308978T3 (es) * 1999-04-09 2008-12-16 Ortho-Mcneil Pharmaceutical, Inc. Composicion farmaceutica de eritropoyetina.
KR100399156B1 (ko) * 1999-11-19 2003-09-26 주식회사 엘지생명과학 α-인터페론의 용액제형
CN1175901C (zh) * 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
AU783246C (en) * 1999-12-14 2007-03-15 Asahi Kasei Kabushiki Kaisha Stabilizing diluent for polypeptides and antigens
JP4536194B2 (ja) * 2000-02-17 2010-09-01 大日本住友製薬株式会社 安定な注射用製剤
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
ATE402733T1 (de) * 2001-04-04 2008-08-15 Alza Corp Transdermales verabreichungsgerät mittels elektrotransport mit einer kompatiblen antimikrobiellen reservoir-lösung
WO2002083165A1 (fr) * 2001-04-10 2002-10-24 Sumitomo Pharmaceuticals Co., Ltd. Preparations stables destinees a etre injectees
LT4947B (lt) 2001-09-26 2002-08-26 Biotechnologijos Institutas Interferono alfa farmacinė kompozicija
US6830744B2 (en) * 2002-05-31 2004-12-14 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US20050232899A1 (en) * 2002-05-31 2005-10-20 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
US7585647B2 (en) 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
WO2005074650A2 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
CN1724567B (zh) * 2004-07-22 2010-08-18 北京三元基因工程有限公司 一种稳定的重组人干扰素α1b水溶液
CN101039660B (zh) 2004-08-12 2010-10-06 先灵公司 稳定的聚乙二醇化干扰素制剂
US20060204474A1 (en) * 2005-02-25 2006-09-14 Coroneo Minas T Treatment of epithelial layer lesions
ES2302402B1 (es) 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
CU23432B6 (es) 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
US8679472B1 (en) 2006-10-05 2014-03-25 Merck, Sharp & Dohme Corp. Crystal of human interferon alpha 2B in complex with zinc
BRPI0810622A2 (pt) 2007-05-02 2020-10-13 Ambrx, Inc. polipeptídeos de interferon beta modificados e seus usos
EP2212432A4 (en) * 2007-10-22 2011-10-19 Schering Corp COMPLETELY HUMAN ANTI-VEGF ANTIBODIES AND USE PROCEDURES
EP2286359A2 (en) * 2008-03-27 2011-02-23 Medtronic, Inc. Method and system to define patient specific therapeutic regimens by means of pharmacokinetic and pharmacodynamic tools
MX2010013759A (es) 2008-06-13 2011-05-25 Proyecto Biomedicina Cima Sl Conjugados para la administracion de compuestos biologicamente activos.
KR101939557B1 (ko) 2008-10-17 2019-01-17 사노피-아벤티스 도이칠란트 게엠베하 인슐린과 ｇｌｐ－1 효능제의 병용물
KR101303388B1 (ko) 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
BR112013032188A2 (pt) 2011-06-23 2016-12-20 Digna Biotech Sl composição, produto e método para tratar pacientes com hepatite c crônica
KR20150074167A (ko) 2012-10-26 2015-07-01 루핀 리미티드 Ｐｅｇ 인터페론 알파-2ｂ의 안정한 약학 조성물
UA117480C2 (uk) 2013-04-03 2018-08-10 Санофі Лікування цукрового діабету за допомогою складу інсуліну тривалої дії
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
ES2524516B1 (es) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
WO2016046101A1 (en) * 2014-09-23 2016-03-31 F. Hoffmann-La Roche Ag Stable, benzyl alcohol-free aqueous solution formulations containing alpha-type interferon
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
MA45276A (fr) * 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
RU2623050C2 (ru) * 2015-12-03 2017-06-21 Виталий Эдуардович Боровиков Раствор хондроитина сульфата для внутримышечного введения и способ его получения
KR200492470Y1 (ko) 2020-03-26 2020-10-21 사공탁 빌라 주택용 쓰레기 수거함
RU2768656C1 (ru) * 2021-09-10 2022-03-24 Илья Александрович Марков Противовирусное средство в жидкой форме и способ его приготовления
CN113797318B (zh) * 2021-10-26 2023-06-30 深圳科兴药业有限公司 一种干扰素组合物及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0082481B2 (en) * 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
JPS59176216A (ja) * 1983-03-28 1984-10-05 Sumitomo Chem Co Ltd 有用なインタ−フエロン製剤
US4680175A (en) * 1984-02-07 1987-07-14 Interferon Sciences, Inc. Interferon administration vehicles
JPS60243028A (ja) * 1984-04-28 1985-12-03 Kyowa Hakko Kogyo Co Ltd インタ−フエロンの可溶化方法
US4606917A (en) * 1984-10-03 1986-08-19 Syntex (U.S.A) Inc. Synergistic antiviral composition
US4857316A (en) * 1984-10-03 1989-08-15 Syntex (U.S.A.) Inc. Synergistic antiviral composition
JPS61277633A (ja) * 1985-05-31 1986-12-08 Toray Ind Inc インタ−フエロン組成物
US4847079A (en) * 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
EP0284249A1 (en) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Lyophilized lymphokine composition
US5266310A (en) * 1987-09-17 1993-11-30 Boehringer Ingelheim International Gmbh Stabilization of therapeutically active proteins in pharmaceutical preparations
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
JP3292894B2 (ja) * 1993-05-12 2002-06-17 日本電信電話株式会社 集積化受光回路

Also Published As

Publication number Publication date
ATE194774T1 (de) 2000-08-15
HU225494B1 (en) 2007-01-29
HK1008813A1 (en) 1999-05-21
EP0970703B1 (en) 2003-07-16
ES2148568T3 (es) 2000-10-16
JP3978228B2 (ja) 2007-09-19
JPH10506912A (ja) 1998-07-07
CZ296961B6 (cs) 2006-08-16
CZ110497A3 (en) 1997-09-17
DK0777495T3 (da) 2000-11-06
PT777495E (pt) 2000-12-29
CN1160355A (zh) 1997-09-24
FI116558B (fi) 2005-12-30
AU3727995A (en) 1996-05-02
FI971486A (fi) 1997-04-10
AU708337B2 (en) 1999-08-05
SK282949B6 (sk) 2003-01-09
DE69518084T2 (de) 2001-03-22
PL183797B1 (pl) 2002-07-31
EP0777495A1 (en) 1997-06-11
ATE245033T1 (de) 2003-08-15
FI971486A0 (fi) 1997-04-10
SK43997A3 (en) 1997-10-08
DE69518084D1 (de) 2000-08-24
KR970706017A (ko) 1997-11-03
DE69531314T2 (de) 2004-05-13
US5766582A (en) 1998-06-16
ES2198830T3 (es) 2004-02-01
EP0777495B1 (en) 2000-07-19
NO320604B1 (no) 2005-12-27
DE69531314D1 (de) 2003-08-21
NZ294464A (en) 1999-03-29
EP0970703A1 (en) 2000-01-12
WO1996011018A1 (en) 1996-04-18
JP2006193536A (ja) 2006-07-27
RU2157236C2 (ru) 2000-10-10
CA2201749A1 (en) 1996-04-18
GR3034619T3 (en) 2001-01-31
CN1102408C (zh) 2003-03-05
HUT77287A (hu) 1998-03-30
MX9702578A (es) 1997-07-31
NO971633D0 (no) 1997-04-10
NO971633L (no) 1997-04-10
KR100401401B1 (ko) 2004-02-18
PL319603A1 (en) 1997-08-18
BR9509313A (pt) 1998-01-27
FI117377B (fi) 2006-09-29
UA42028C2 (uk) 2001-10-15
CA2201749C (en) 1999-06-15
US5935566A (en) 1999-08-10

Similar Documents

Publication Publication Date Title
FI20055562A (fi) Alfa-interferonin stabiilit vesiliuosformulaatit
ATE355850T1 (de) Lyophilisierte hgf-zubereitungen
AR025243A1 (es) Composicion liquida de pesticida.
DE69526970D1 (de) Stabilisierte lösungen enthaltend 2-chloro-2'-deoxyadenosin
NZ505821A (en) Pharmaceutical compositions of uridine triphosphate
IL79084A0 (en) E-isomers of n alpha-(2-cyano-2-alkoximinoacetyl)-amino acid derivatives and peptides,their preparation and their use as pesticides
DK0490549T3 (da) Stabilisering af calcitonin-holdige farmaceutiske præparater
DK0381617T3 (da) Desinfektions- og rensemiddel til kontaktlinser
DE3863859D1 (de) Stabile, injizierbare loesungen von salzen von vincristin.
KR950005325A (ko) 제약 조성물
MX9305523A (es) Composiciones quimoterapeuticas mejoradas frente a infecciones microbianas en peces, la reparacion y uso de las mismas.
DK443988A (da) Injektionspraeparat indeholdende modificeret tpa
KR870008581A (ko) 안정하고 주사가능한 1,4-디히드록시-5,8-비스 [2-(2-히드록시에틸아미노)에틸아미노]안트라퀴논, 디히드로클로라이드의 약학적 배합제제
FR2718923B1 (fr) Composition désinfectante en solution aqueuse renfermant de l'orthophtalaldéhyde.
ATE332133T1 (de) Pharmazeutische zusammensetzung enthaltend glyzin als stabilisator
DK0506563T3 (da) Alginsyresuspension
PT806206E (pt) Composicoes aquosas que contem ciprofloxacina e utilizacao e processo correspondentes
SE9502927D0 (sv) Solution containing IGF-I
RU2002120178A (ru) Водный раствор интерферона-альфа-два человека для инъекций
DE69905228D1 (de) Ammoniumsalze von Phenoxy-Isobuttersäure und diese enthaltende pharmazeutische Formulierungen

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 117377

Country of ref document: FI

PC Transfer of assignment of patent

Owner name: MERCK SHARP & DOHME CORP.

MA Patent expired